E2F1 and liver cancer: In addition, as shown in Figure 4E, the results of the immunohistochemistry assay revealed that the expression of E2F1 in liver cancer tissues was significantly increased compared with that of adjacent tissues and was also the highest in the cisplatin-resistant drug group.